1h Free Analyst Time
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Drugs In Development, 2022, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Male Health, Oncology, Central Nervous System, Musculoskeletal Disorders, Ophthalmology and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Psoriasis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Female Sexual Dysfunction, Glaucoma, Male Sexual Dysfunction, Melanoma, Ocular Hypertension, Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Post-Operative Pain, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Adenosine Receptor A3 (ADORA3) - Overview
- Adenosine Receptor A3 (ADORA3) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
- Can-Fite BioPharma Ltd
- Future Medicine Co Ltd
- Neumentum Inc
- Palo BioFarma SL
- Protheragen Inc
- Adenosine Receptor A3 (ADORA3) - Drug Profiles
- Cannabinoids - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CF-602 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DPP-017 - Drug Profile
- Product Description
- Mechanism Of Action
- FM-1203 - Drug Profile
- Product Description
- Mechanism Of Action
- LJ-1888 - Drug Profile
- Product Description
- Mechanism Of Action
- LJ-2698 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- namodenoson - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NTM-006 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PBF-1650 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PBF-677 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- piclidenoson - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
- Product Description
- Mechanism Of Action
- Adenosine Receptor A3 (ADORA3) - Dormant Products
- Adenosine Receptor A3 (ADORA3) - Discontinued Products
- Adenosine Receptor A3 (ADORA3) - Product Development Milestones
- Featured News & Press Releases
- Jul 11, 2022: Can-Fite to submit FDA & EMA registration plans for piclidenoson in the oral treatment of moderate to severe psoriasis
- Jun 29, 2022: Can-Fite announces positive top-line results from piclidenoson phase III COMFORT study in moderate to severe psoriasis
- Jun 24, 2022: Can-Fite’s CF602 reverses erectile dysfunction in diabetic pre-clinical model: study published in peer-reviewed Journal Andrologia
- Jun 09, 2022: Can-Fite announces publication of clinical study data for piclidenoson and namodenoson in scientific journal
- May 16, 2022: Can-Fite granted key NASH Patent in Israel
- May 02, 2022: Can-Fite’s CEO to present Namodenoson’s efficacy in liver cancer as expert speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
- Apr 05, 2022: Can-Fite is developing a topical Piclidenoson psoriasis treatment that shows efficacy in a preclinical model: potential complementary product to its phase III oral psoriasis drug
- Mar 28, 2022: Can-Fite to present at Dermatology Drug Development Summit Europe on April 6, 2022
- Mar 14, 2022: Can-Fite: Namodenoson’s treatment of liver fibrosis receives Notice of Allowance from U.S. Patent Office
- Mar 08, 2022: Can-Fite’s phase III psoriasis study data expected Q2 2022
- Feb 01, 2022: Can-Fite enrols first subject in Phase IIb NASH trial
- Jan 13, 2022: Prior to phase III psoriasis data release Can Fite reports that piclidenoson destroys pathological skin cells in vitro
- Jan 10, 2022: Can-Fite to conduct investor meetings during the J.P. Morgan Healthcare Conference
- Dec 29, 2021: Following complete clearance of cancer lesions in advanced liver cancer patient, Can-Fite is filing patent applications for the treatment of various advanced solid tumors
- Dec 20, 2021: Liver cancer patient treated with Can-Fite’s namodenoson clears all cancer lesions under open label extension of phase II Study
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Can-Fite BioPharma Ltd, 2022
- Pipeline by Future Medicine Co Ltd, 2022
- Pipeline by Neumentum Inc, 2022
- Pipeline by Palo BioFarma SL, 2022
- Pipeline by Protheragen Inc, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Dormant Products, 2022 (Contd..2)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Can-Fite BioPharma Ltd
- Future Medicine Co Ltd
- Neumentum Inc
- Palo BioFarma SL
- Protheragen Inc
